Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03606577 | An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients(IFM 2018-04) | active not recruiting | Phase 2 | 50 | Nantes University HospitalOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04856137 | A Phase I/II Study of Diffuse Large B-cell Lymphoma(DLBL) | not yet recruiting | Phase 1 / Phase 2 | 74 | National Health Research Institutes, TaiwanOTHER |
| 0 |
| Apr 23, 2021 |
| clinicaltrials |
| NCT04771507 | A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)(IbruOnOff) | recruiting | Phase 1 / Phase 2 | 50 | Jeanette LundinOTHER | 2 | Feb 25, 2021 | clinicaltrials |
| NCT03356054 | Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse(HOVON 136 NHL) | recruiting | Phase 1 / Phase 2 | 37 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04440436 | Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients | recruiting | Phase 1 / Phase 2 | 52 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT04451200 | Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning(BUSEQ) | not yet recruiting | Phase 2 | 82 | Institut Paoli-CalmettesOTHER | 0 | Nov 17, 2020 | clinicaltrials |
| NCT02657785 | Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02836158 | Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03669965 | KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera | active not recruiting | Phase 2 | 20 | Kartos Therapeutics, Inc.INDUSTRY | 6 | Jul 31, 2020 | clinicaltrials |
| NCT03793517 | Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT | recruiting | Phase 2 / Phase 3 | 55 | Peking University People's HospitalOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT03815279 | A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)(iStopMM) | enrolling by invitation | Phase 2 | 80 | Landspitali University HospitalOTHER | 1 | Aug 16, 2019 | clinicaltrials |
| NCT04025450 | Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03980002 | A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL(BDHCLL001) | recruiting | Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 10, 2019 | clinicaltrials |
| NCT03196414 | Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 10 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT02259556 | CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas(CART30) | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT02497898 | Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma | not yet recruiting | Phase 2 | 1,000 | The First People's Hospital of ChangzhouOTHER | 0 | Jul 15, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Apr 28, 2021source: clinicaltrials